Incretin-based Combination Therapy in Type 2 Diabetes Mellitus.
10.5124/jkma.2009.52.10.1030
- Author:
Jae Hyeon KIM
1
;
Myung Shik LEE
Author Information
1. Division of Endocrinology and Metabolism/Department of Internal Medicine, Sungkyunkwan University School of Medicine, Korea. mslee0923@skku.edu
- Publication Type:Original Article ; Clinical Trial
- Keywords:
DPP-4 inhibitors;
GLP-1 mimetics;
Incretin;
Type 2 diabetes
- MeSH:
Adamantane;
Diabetes Mellitus, Type 2;
Humans;
Incretins;
Insulin;
Nitriles;
Patient Selection;
Peptides;
Pyrazines;
Pyrrolidines;
Sitagliptin Phosphate;
Triazoles;
Venoms;
Weight Gain;
Weight Loss
- From:Journal of the Korean Medical Association
2009;52(10):1030-1036
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
While there are many therapies for type 2 diabetes are available including insulin secretagogues, insulin sensitizers and exogenous insulin, many patients are unable to reach recommended therapeutic targets. Incretin-based therapies have recently been introduced into clinical practice, and these novel therapies may make it possible to achieve improved glycemic control either with no weight gain (dipeptidyl peptidase-4 [DPP-4] inhibitors sitagliptin and vildagliptin, or with weight loss (glucagon-like peptide-1 [GLP-1] mimetics exenatide and liraglutide). This article aims to provide an overview of efficacy and safety data regarding incretinbased clinical trials in type 2 diabetic patients, and propose a systematic approach to treatment including patient selection and optimal treatment combination. In addition, preclinical data suggest that incretin-based therapies may also preserve-cell function. Therefore, these agents hold out promise of a truly disease-modifying therapy that would target the progressive nature of type 2 diabetes. Additional clinical trials will be required to test such hypothesis.
